Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating whether extended-dose interval immunotherapy provides similar or better efficacy and safety compared …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage [EARLY_Phase 1]
A pilot Phase 1 study at Rutgers is evaluating circulating tumor DNA as a biomarker in early-stage triple-negative and HER2-positive breast …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer [Phase 2]
This clinical trial update describes a Phase 2 study of genomically guided radiation therapy for treating triple-negative breast cancer, cur…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study of Screening Brain MRIs in Stage IV Breast Cancer
A clinical trial at H. Lee Moffitt Cancer Center is evaluating the use of screening brain MRIs in patients with Stage IV breast cancer, incl…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Tier Palliative Care For Patients With Advanced Heart Failure or Cancer [NA]
This clinical trial update describes a Mount Sinai–sponsored tiered palliative care study for patients with advanced heart failure or cancer…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating tiragolumab in combination with atezolizumab and chemotherapy for triple-negative breast cancer is currently acti…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer [Phase 1]
Phase 1 trial update for DC1 therapy (DecipHER) in early-stage triple-negative breast cancer and ER-low positive breast cancer. The study is…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung [Phase 2]
A Phase 2 randomized trial evaluating stereotactic body radiation therapy (SBRT) in patients with oligoprogressive metastatic breast and lun…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) [NA]
A prospective biobanking study by Institut Curie (SCANDARE) aims to understand how tumor molecular alterations relate to the tumor microenvi…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) [Phase 2]
A Phase 2 neoadjuvant trial evaluating serplulimab plus weekly paclitaxel and carboplatin in triple-negative breast cancer; the study status…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating sacituzumab govitecan at an alternative dose and schedule in advanced triple-negative breast cancer is…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC [Phase 3]
Phase 3 clinical trial evaluating SBRT in combination with a PD-1 inhibitor and chemotherapy for early-stage triple-negative breast cancer; …
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC [Phase 2]
Phase 2 study of HB0025 in combination with nab-paclitaxel as first-line therapy for triple-negative breast cancer, currently enrolling by i…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy [Phase 2]
Phase 2 neoadjuvant trial for early triple-negative breast cancer evaluating a response-guided approach using Iparomlimab and Tuvonralimab i…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 3]
A Phase 3 trial comparing SKB264 to investigator's choice chemotherapy in unresectable recurrent or metastatic triple-negative breast cancer…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) [Phase 3]
Phase 3 trial update comparing datopotamab deruxtecan (Dato-DXd) versus investigator's choice chemotherapy in locally recurrent or metastati…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer [Phase 2]
Phase II multicenter trial evaluating Sacituzumab Tirumotecan in combination with KL-A167 as neoadjuvant therapy for triple-negative breast …
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer [Phase 1]
Phase 1 study evaluating a personalized cancer vaccine immunotherapy in combination with a checkpoint inhibitor for triple-negative breast c…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC [Phase 2]
Phase II study evaluating the safety and efficacy of a triple combination of Zimberelimab, Domvanalimab, and Sacituzumab Govitecan as first-…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer [NA]
This clinical trial investigates pre-operative stereotactic ablative radiotherapy (SABR) with or without caloric restriction for early-stage…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer [Phase 3]
Phase 3 trial comparing FDA018-ADC against investigator's choice chemotherapy for locally advanced, recurrent, or metastatic triple-negative…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC [Phase 2]
A Phase 2 clinical trial is evaluating the combination of sacituzumab govitecan and bevacizumab in metastatic triple-negative breast cancer,…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) [NA]
The CUPCAKE study is currently recruiting to evaluate early detection of relapse in patients with triple-negative breast cancer.
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) [Phase 3]
Phase 3 clinical trial evaluating antivascular therapy in combination with chemotherapy versus chemotherapy alone as adjuvant treatment for …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers [Phase 2]
Phase 2 clinical trial evaluating standard-of-care chemotherapy with or without tocilizumab for metastatic breast cancer, including triple-n…